Pancreatic Neoplasms: Clinical Trials

3,889 trials for Pancreatic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1599 completed, 619 unknown, 611 recruiting, 416 terminated. 1333 Phase 2, 1090 Phase 1, 723 Not applicable, 227 Phase 3, 86 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 21333Completed 568, Terminated 183, Recruiting 180, Unknown 168, Active not recruiting 98, Not yet recruiting 63, Withdrawn 60, Suspended 11, Enrolling by invitation 2
Phase 11090Completed 490, Recruiting 160, Terminated 157, Unknown 103, Active not recruiting 82, Withdrawn 52, Not yet recruiting 34, Suspended 12
Not applicable723Completed 262, Unknown 161, Recruiting 127, Terminated 51, Not yet recruiting 43, Active not recruiting 40, Withdrawn 33, Enrolling by invitation 4, Suspended 2
Phase 3227Completed 96, Recruiting 39, Unknown 34, Terminated 29, Active not recruiting 12, Not yet recruiting 10, Withdrawn 5, Suspended 2
Early Phase 186Recruiting 17, Completed 16, Unknown 15, Terminated 12, Withdrawn 10, Active not recruiting 8, Not yet recruiting 8
Phase 448Completed 20, Unknown 14, Recruiting 4, Terminated 4, Active not recruiting 2, Not yet recruiting 2, Withdrawn 2

Follow Pancreatic Neoplasms: new trials by email Literature Review of Pancreatic Neoplasms trials Research Report on Pancreatic Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma
Phase 1 / Phase 2WithdrawnLisata Therapeutics, Inc.2030-01-012025-06-06
Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms
Clinical Intervention or Procedure, Electronic Health Record Review, Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas - Pancreatic Neoplasm, Pancreatic Neuroendocrine Tumor
Not applicableEnrolling by invitationOhio State University Comprehensive Cancer Center122027-10-012026-10-13
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
Rintatolimod - Pancreatic Cancer
Phase 2SuspendedAIM ImmunoTech Inc.902027-08-012026-08-19
Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation
DN022150+AG( Stage I ), DN022150+AG(Stage II), placebo+AG(Stage II) - Pancreatic Cancer, Pancreatic Carcinoma
Phase 2 / Phase 3Not yet recruitingJiangxi Kvvit Pharmaceutical Co., Ltd.4652027-06-062026-06-18
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)312027-06-012026-10-22
Daraxonrasib in Resectable PDAC
Daraxonrasib, Surgical Resection, Adjuvant Chemotherapy - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Phase 1Not yet recruitingDana-Farber Cancer Institute302027-04-132026-10-27
A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer
EF-009 - Pancreatic Cancer
Phase 1 / Phase 2Not yet recruitingEverfront Biotech Co., Ltd.302027-04-012026-09-11
A Prospective Study of Concurrent Hyperthermia, Chemotherapy and Radiotherapy in Borderline and Locally Advanced Pancreatic Cancer (PANHEAT)
Hyperthermia plus neoadjuvant chemotherapy/radiotherapy Arm Description: Hyperthermia plus neoadjuvant chemotherapy (mFOLFIRINOX/nab Paclitaxel) followed by a) surgically resectable: Hyp - Borderline and Locally Advanced Pancreatic Cancer
Not applicableNot yet recruitingFernando Pessoa Canarias University602027-03-312026-09-24
A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer
Navlimetostat, mFOLFIRINOX Treatment Regimen - Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 / Phase 2Not yet recruitingDaniel Nussbaum, M.D.182027-01-152026-11-02
Predicting Pancreatic Fistula After Pancreatic Surgery Using Preoperative Immunity
blood sampling - Pancreatic Cancer
Not yet recruitingInstitut Paoli-Calmettes3102027-01-042026-09-18
TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)
Music-assisted relaxation and imagery (MARI) - Surgery, Stomach Cancer
Not applicableNot yet recruitingCase Comprehensive Cancer Center202027-01-012026-08-05
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
vilastobart (XTX101), Retifanlimab - Pancreatic Cancer Metastatic
Phase 2Not yet recruitingMassachusetts General Hospital402027-01-012026-08-14
A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
MRG004A plus best supportive care, Placebo plus best supportive care - Advanced Pancreatic Cancer
Phase 3Not yet recruitingLepu Biopharma Co., Ltd.2312027-01-012026-05-15
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer
Pancreatic Cancer, Advanced or Metastatic
Not yet recruitingUniversity of Maryland, Baltimore4502027-01-012026-11-06
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
Actigraphy, Online Mindfulness Meditation, Smartphone Application-based Intervention - Hepatocellular Carcinoma, Pancreas Cancer
Not applicableNot yet recruitingCity of Hope Medical Center702027-01-012026-11-10
64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
Biospecimen Collection, Copper Cu 64-DOTA-A2DM, Positron Emission Tomography - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Phase 1Not yet recruitingCity of Hope Medical Center152026-12-162026-05-27
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Biospecimen Collection, Computed Tomography, Incomplete Freund''s Adjuvant - Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm
Phase 2Not yet recruitingRoswell Park Cancer Institute602026-12-152026-10-20
A Decision Support Tool for Pancreatic Cancer Screening -Aim 2
Electronic Decision Support Tool - Pancreas Cancer
Not applicableNot yet recruitingUNC Lineberger Comprehensive Cancer Center402026-12-082026-11-05
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
ANO31905, AG [gemcitabine+nab-paclitaxel], mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil] - Pancreatic Cancer
Phase 1 / Phase 2RecruitingAnova Innovation Limited842026-12-012026-10-23
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
LG00313112 - Ovarian Cancer, Small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingLG Chem2502026-12-012026-08-07

Showing 20 of 3889. Sign in to see all of them.

Narrower conditions

Colorectal Neoplasms (430)  ·  Stomach Neoplasms (398)  ·  Breast Neoplasms (358)  ·  Neoplasms (325)  ·  Ovarian Neoplasms (296)  ·  Carcinoma, Non-Small-Cell Lung (283)  ·  Lung Neoplasms (278)  ·  Colonic Neoplasms (254)  ·  Esophageal Neoplasms (243)  ·  Neoplasm Metastasis (236)  ·  Prostatic Neoplasms (193)  ·  Liver Neoplasms (182)  ·  Melanoma (162)  ·  Head and Neck Neoplasms (141)

Broader conditions

Endocrine System Diseases (3879)  ·  Endocrine Gland Neoplasms (3876)  ·  Digestive System Diseases (3875)  ·  Neoplasms by Site (3873)  ·  Digestive System Neoplasms (3863)  ·  Pancreatic Diseases (3837)  ·  Neoplasms (3564)  ·  Neoplasms by Histologic Type (924)  ·  Gastrointestinal Diseases (837)  ·  Neoplasms, Glandular and Epithelial (810)  ·  Gastrointestinal Neoplasms (739)  ·  Intestinal Diseases (670)  ·  Intestinal Neoplasms (651)  ·  Pathological Conditions, Signs and Symptoms (631)  ·  Colonic Diseases (607)

Interventions

Gemcitabine (701)  ·  130-nm albumin-bound paclitaxel (212)  ·  Fluorouracil (199)  ·  Oxaliplatin (181)  ·  Albumin-Bound Paclitaxel (162)  ·  Capecitabine (147)  ·  Leucovorin (139)  ·  Irinotecan (117)  ·  Radiotherapy (98)  ·  pembrolizumab (89)  ·  Taxes (83)  ·  Cisplatin (82)  ·  Erlotinib Hydrochloride (71)  ·  Radiosurgery (71)  ·  Bevacizumab (61)

Sponsors

National Cancer Institute (NCI) (125)  ·  M.D. Anderson Cancer Center (65)  ·  Memorial Sloan Kettering Cancer Center (52)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (52)  ·  Fudan University (50)  ·  Mayo Clinic (40)  ·  Peking Union Medical College Hospital (35)  ·  Washington University School of Medicine (35)  ·  Changhai Hospital (34)  ·  H. Lee Moffitt Cancer Center and Research Institute (34)  ·  Dana-Farber Cancer Institute (29)  ·  Eli Lilly and Company (27)  ·  Massachusetts General Hospital (27)  ·  IRCCS San Raffaele (26)  ·  Ruijin Hospital (26)

Countries

United States (1908)  ·  China (578)  ·  France (244)  ·  Italy (222)  ·  Spain (202)  ·  Canada (194)  ·  South Korea (193)  ·  United Kingdom (182)  ·  Germany (177)  ·  Australia (129)  ·  Netherlands (118)  ·  Belgium (109)  ·  Japan (94)  ·  Taiwan (87)  ·  Denmark (76)

Top investigators

Shyam Varadarajulu, MD (12)  ·  Saleh K Saleh, MD (11)  ·  Michele Reni, MD (8)  ·  Dung Le, MD (7)  ·  Vincent Chung (7)  ·  Andrew Ko, MD (6)

Results publications

PMID 39863139, PMID 37598000, PMID 21561347, PMID 23433878, PMID 24131140, PMID 28733257, PMID 33337539, PMID 15273542, PMID 15855973, PMID 21420083, PMID 23547081, PMID 28040257, PMID 40056080, PMID 42836590, PMID 15908661, PMID 18494054, PMID 18992248, PMID 20620274, PMID 20842054, PMID 21831266, PMID 22321518, PMID 22341257, PMID 22658389, PMID 23229886, PMID 24368638, PMID 24578254, PMID 24840647, PMID 24901360, PMID 24982456, PMID 25512461, PMID 25733127, PMID 26341722, PMID 26422979, PMID 26615328, PMID 26879162, PMID 27275632, PMID 27650271, PMID 28025154, PMID 29119276, PMID 29223478, PMID 29325707, PMID 29508247, PMID 29800971, PMID 29929491, PMID 29941289, PMID 30834048, PMID 31481506, PMID 31654634, PMID 32526235, PMID 32583392

NIH funding

2023 (17), 2016 (15), P30CA006973 (14), P30CA016672 (14), P30CA033572 (14), 2014 (13), 2015 (12), 2017 (12), 2019 (12), 2025 (11), P30CA015083 (11), 2018 (10), P30CA068485 (10), U10CA031946 (9), UM1CA186689 (9)